Previous studies reported that a STING agonist, diABZI, effectively blocks SARS-CoV-2 infection.2,3 Considering the critical role of STING in aberrant cytokine responses in the late phase of infection, it is vital to investigate whether diABZI leads to heave tissue damage or uncontrollable immunopathology or not. This evidence concerns the gene STING1 and infection.